Drug Trial Radar · NCT07010692
Treating Basal and Squamous Cell Carcinomas With Fractional Laser and Tirbanibulin Ointment
Last checked: Nov 20, 2026Latest source record: Sep 17, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
100
Planned (sponsor's estimate)
Start
May 16, 2025
Primary completion
May 2030
Study completion Jun 2030
Sponsor
- Lead sponsor
- Bruce Robinson, MDAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Jun 8, 2025
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Non randomized
- Model
- Factorial
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The investigators seek to evaluate the effectiveness of fractional laser therapy and tirbanibulin ointment to treat squamous and basal cell carcinomas. This will be executed by using both thulium and erbium lasers on previously biopsy-confirmed SCCs and BCCs and applying bulk heating methods. Then, depending on the level of invasiveness, subjects may be instructed to apply the ointment over the course of five nights immediately following the treatment. The intention of this study is to minimize the need for invasive surgical procedures so as to optimize the cosmetic appearance, and provide a treatment option that is beneficial for a wide range of individuals.
Conditions
- Keratinocyte Carcinoma
- Basal Cell Carcinomas
- Squamous Cell Carcinoma
- Skin Cancer
Interventions
Tirbanibulin ointment 1%Drug
Tirbanibulin ointment is applied for 5 nights following the in-office fractional laser procedure for patients with more advanced carcinomas.
non-ablative fractional laserDevice
Every skin cancer will be treated with two wavelengths (1550nm and 1927nm) of a non-ablative fractional laser.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Clearance of skin cancer by evidence of no clinical and/or histological recurrence after 5 years.Time frame: From enrollment to the end of follow-up monitoring at 5 years.
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Bruce Robinson, MD
New York, New York · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.